. 2020 Jun 29;111(8):2872–2882. doi: 10.1111/cas.14505

TABLE 1.

Reversal effect of CC‐671 in non‐small cell lung cancer cells overexpressing ABCG2 transporter

Treatment	IC₅₀ value ± SD ^a (μmol/L, resistance‐fold ^b )
Treatment	NCI‐H460	NCI‐H460/MX20	A549	A549/MX10
Mitoxantrone	0.011 ± 0.003 (1.00)	1.437 ± 0.326 (125.13)	0.026 ± 0.009 (1.00)	2.401 ± 0.486 (76.78)
+ CC‐671 0.1 μmol/L	0.014 ± 0.006 (1.20)	0.081 ± 0.006 (7.09)^*	0.027 ± 0.004 (1.07)	0.633 ± 0.255 (20.24)^*
+ CC‐671 0.3 μmol/L	0.013 ± 0.004 (1.16)	0.053 ± 0.004 (4.63)^*	0.021 ± 0.005 (0.83)	0.252 ± 0.064 (8.06)^*
+ CC‐671 1 μmol/L	0.012 ± 0.002 (1.07)	0.038 ± 0.002 (3.34)^*	0.025 ± 0.008 (0.96)	0.144 ± 0.032 (4.61) ^*
+ Ko143 1 μmol/L	0.014 ± 0.007 (1.19)	0.044 ± 0.003 (3.87)^*	0.028 ± 0.007 (1.10)	0.181 ± 0.040 (5.78) ^*
Topotecan	0.043 ± 0.025 (1.00)	3.003 ± 0.641 (69.12)	0.035 ± 0.003 (1.00)	1.401 ± 0.486 (40.03)
+ CC‐671 0.1 μmol/L	0.053 ± 0.008 (1.23)	0.504 ± 0.115 (11.61)^*	0.033 ± 0.004 (0.94)	0.531 ± 0.147 (15.17) ^*
+ CC‐671 0.3 μmol/L	0.068 ± 0.024 (1.56)	0.411 ± 0.095 (9.46)^*	0.032 ± 0.007 (0.92)	0.326 ± 0.034 (9.31) ^*
+ CC‐671 1 μmol/L	0.064 ± 0.018 (1.46)	0.242 ± 0.040 (5.58)^*	0.041 ± 0.011 (1.17)	0.166 ± 0.029 (4.74) ^*
+ Ko143 1 μmol/L	0.059 ± 0.028 (1.37)	0.218 ± 0.088 (5.01)^*	0.028 ± 0.004 (0.82)	0.210 ± 0.021 (6.06) ^*
Cisplatin	3.730 ± 0.834 (1.00)	5.198 ± 2.412 (1.39)	4.730 ± 0.534 (1.00)	3.991 ± 0.187 (0.84)
+ CC‐671 1 μmol/L	3.581 ± 0.388 (0.96)	5.106 ± 1.334 (1.37)	4.987 ± 0.561 (0.95)	4.847 ± 0.406 (1.02)
+ Ko143 1 μmol/L	3.067 ± 0.947 (0.82)	4.028 ± 0.581 (1.08)	4.991 ± 0.287 (1.06)	4.067 ± 0.347 (0.86)

^{^a}

IC₅₀ values are represented as mean ± SD of at least 3 independent experiments carried out in triplicate.

^{^b}

Calculated by dividing the IC₅₀ values of substrates in the presence or absence of inhibitor by the IC₅₀ of parental cells without inhibitor.

P < .05 vs. control group without reversal agent.